Zhaoyang Y. Zeng

Xiaoxita, CN 
Xiaoxita, CN 

Overview

Zhaoyang Zeng practices practicing medicine in Xiaoxita, China.

Their clinical expertise encompasses Pyle Disease, Maturity Onset Diabetes of the Young, Autoimmune Polyglandular Syndrome Type 2, and Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy (APECED).

They are actively involved in clinical research, co-authoring 8 peer reviewed articles and participating in 2 clinical trials.

Locations

Xiaoxita, 443000, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized, Phase 3, Open-label Trial Comparing the Effect of Tirzepatide Once Weekly Versus Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes on Metformin With or Without a Sulfonylurea
A Randomized, Phase 3, Open-label Trial Comparing the Effect of Tirzepatide Once Weekly Versus Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes on Metformin With or Without a Sulfonylurea
Enrollment Status: Completed
Publish Date: January 06, 2023
Intervention Type: Drug
Study Drugs: Tirzepatide, Insulin Glargine
Study Phase: Phase 3
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro, Both in Combination With Insulin Glargine or Insulin Degludec in Adults With Type 2 Diabetes
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro, Both in Combination With Insulin Glargine or Insulin Degludec in Adults With Type 2 Diabetes
Enrollment Status: Completed
Publish Date: February 08, 2022
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

8 Total Publications

Genome analysis of Staphylococcus caprae indicates potential health risks associated with antimicrobial resistance and virulence factors.
Genome analysis of Staphylococcus caprae indicates potential health risks associated with antimicrobial resistance and virulence factors.
Journal: Canadian journal of microbiology
Published: June 25, 2026

Frequently Asked Questions about Zhaoyang Y. Zeng

Is Zhaoyang Y. Zeng a top-rated expert for Pyle Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Zhaoyang Y. Zeng is classified as an Experienced expert for Pyle Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Zhaoyang Y. Zeng participate in research or clinical trials?

Yes. Zhaoyang Y. Zeng has published 8 articles and abstracts on conditions like Pyle Disease. You can view a list of Zhaoyang Y. Zeng's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Zeng's expertise for a condition
ConditionClose
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile